Related Experiment Videos
Anticardiolipin antibodies in Behçet's disease
R Bergman1, M Lorber, M Lerner
1Department of Dermatology, Rambam Medical Center, Technion-Israel Institute of Technology, Haifa.
The Journal of Dermatology
|March 1, 1990
Summary
Serum IgM anticardiolipin (ACL) antibody levels were significantly elevated in Behçet
Area of Science:
- Rheumatology
- Immunology
- Vascular Medicine
Background:
- Behçet's disease is a multisystem vasculitis of unknown etiology.
- Anticardiolipin (ACL) antibodies are associated with thrombosis in other conditions.
- The role of ACL antibodies in Behçet's disease remains unclear.
Purpose of the Study:
- To investigate the frequency and clinical significance of serum anticardiolipin (ACL) antibody isotypes IgG and IgM in patients with Behçet's disease.
Main Methods:
- Serum samples from 26 patients with Behçet's disease were analyzed for IgG and IgM ACL antibody levels.
- Statistical analysis was performed to correlate ACL antibody levels with clinical parameters.
Main Results:
- A significantly increased frequency of elevated serum IgM ACL antibody levels was observed in Behçet's disease patients.
- Elevated IgM ACL antibody levels did not show a statistically significant correlation with thrombotic events.
- No significant correlation was found between IgM ACL antibodies and colchicine use, antinuclear antibodies, or VDRL test results.
Conclusions:
- Elevated IgM anticardiolipin (ACL) antibody levels are common in Behçet's disease.
- IgM ACL antibodies in Behçet's disease do not appear to be a reliable marker for thrombotic tendency.
- Further research is needed to elucidate the specific role of ACL antibodies in Behçet's disease pathogenesis.